-
REPROCELL Submits Application for Manufacturing and Marketing Approval in Japan for Stem Cell Therapy Stemchymal® for Spinocerebellar Ataxia (SCA3 and SCA6)
YOKOHAMA, Japan, June 24, 2026 /PRNewswire/ — REPROCELL Inc. today announced the submission of an application for manufacturing and marketing approval in Japan for the regenerative medicine product Stemchymal®, for which the company holds exclusive commercialization rights in Japan. The application seeks approval for the use of Stemchymal® to suppress the progression of ataxia in…
-
Nicox Announces Positive Pre-submission Regulatory Feedback in China Supporting NDA filing for NCX 470
Press Release Nicox Announces Positive Pre-submission Regulatory Feedback in China Supporting NDA filing for NCX 470 Exclusive licensee for China, Ocumension, received positive pre-submission regulatory feedback from the Chinese Center for Drug Evaluation (CDE) for NCX 470 Based on this feedback, Ocumension intends to proceed with the New Drug Application (NDA) submission in China Submission…
-
Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
June 05, 2026 20:13 ET | Source: Bluejay Diagnostics, Inc. $8.5 million upfront with up to approximately $15.2 million of potential additional gross proceeds upon the exercise in full of warrants Net proceeds anticipated to extend cash runway into first quarter of 2027, beyond expected FDA submission; if warrants are exercised in full for cash,…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.